ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Fujifilm pictures new pharma-heavy identity with Avigan

Looming end to Xerox tie-up strains push into health care

Fujifilm Chairman and CEO Shigetaka Komori has been a driving force behind the transformation of the company. (Photo by Akira Kodaka)

TOKYO -- Propelled by the wave of keen interest in promising treatments for the coronavirus, Fujifilm Holdings is ready to shed its image as a camera film and copier maker and become known as an operation centered on health care.

The company announces its results for the year ended March on Friday. Market watchers are particularly interested in any comments regarding the flu drug Avigan, one of the most-talked-about candidates to treat COVID-19.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more